Ian Wilde - Novacyt Executive

ALNOV Stock  EUR 0.52  0.01  1.96%   

Executive

Mr. Ian Wilde serves as Member of the Executive Team and Group RA QA Director at NOVACYT S.A. He joined Novacyt in November 2014. He has over 15 years of experience in medical devices from working with smalltomedium sized enterprises and blue chip organizations . He has operational experience at senior management and board levels, and experience in quality system development and regulatory compliance.
Phone33 1 39 46 51 04
Webhttps://www.novacyt.com

Novacyt Management Efficiency

The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt's management efficiency ratios could be used to measure how well Novacyt manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.45 M in total debt with debt to equity ratio (D/E) of 26.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novacyt has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novacyt until it has trouble settling it off, either with new capital or with free cash flow. So, Novacyt's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novacyt sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novacyt to invest in growth at high rates of return. When we think about Novacyt's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Virginie MorgonVivendi SA
46
Veronique DriotArgentinVivendi SA
55
Cyrille BolloreVivendi SA
32
Aliza JabesVivendi SA
55
Said BenaliItissalat Al Maghrib
N/A
Nathalie BricaultVivendi SA
50
Rita FirdawcyItissalat Al Maghrib
N/A
Samir TaziItissalat Al Maghrib
49
Mustafa BoulhannaItissalat Al Maghrib
N/A
Pascal CagniVivendi SA
54
Serkan OkandanItissalat Al Maghrib
N/A
Tawfiq DadouchItissalat Al Maghrib
N/A
Mohamed SuwaidiItissalat Al Maghrib
47
Mohamed HassadItissalat Al Maghrib
60
Basma GuasmiItissalat Al Maghrib
N/A
Boudaoud BrahimItissalat Al Maghrib
N/A
Leila BennaniItissalat Al Maghrib
N/A
Philippe BenacinVivendi SA
59
Amal BourkiItissalat Al Maghrib
N/A
Daniel CamusVivendi SA
63
Abderrahim AjaouiItissalat Al Maghrib
N/A
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 111 people. Novacyt (ALNOV) is traded on Euronext Paris in France and employs 210 people.

Management Performance

Novacyt Leadership Team

Elected by the shareholders, the Novacyt's board of directors comprises two types of representatives: Novacyt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt's management team and ensure that shareholders' interests are well served. Novacyt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Heath, Non-Executive Director
Steve Gibson, Member of the Executive Team, Group Financial Controller
Jim Wicks, Member of the Executive Team, Managing Director Primer Design Division
Mandy Cowling, Member of the Executive Team, Corporate & Investor Relations Manager
Ian Wilde, Head of Quality Assurance and Regulatory Compliance
Eric Peltier, Chief Innovation Officer
David Franks, Chief Officer
Anthony Dyer, Fin. Director
James McCarthy, Acting CFO
James Wakefield, Independent Non-Executive Chairman
Bryan Close, Chief Officer
Paul Oladimeji, Group RD
Paul Eros, Member of the Executive Team, Managing Director Primerdesign Division
Aymeric Perchant, Research and Development Director
Bruce Kaufman, Independent Director
Edwin Snape, Independent Non-Executive Director
Graham Mullis, CEO and Director
JeanPierre Crinelli, Deputy CEO, Director
Grald Ulrich, Chief Devel
Ruth Powell, Member of the Executive Team, Managing Director NOVAprep Division
Juliet Thompson, Independent Non-Executive Director
Phillip Sefton, Member of the Executive Team, Managing Director Lab21 Division
Wendy Karban, Member of the Executive Team, Group Human Resource Manager
Alan Howard, Non-Executive Director

Novacyt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novacyt a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novacyt in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novacyt's short interest history, or implied volatility extrapolated from Novacyt options trading.

Pair Trading with Novacyt

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novacyt position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novacyt will appreciate offsetting losses from the drop in the long position's value.

Moving together with Novacyt Stock

  0.73ALBPK Broadpeak SAPairCorr
  0.89ALCAR CarmatPairCorr
  0.84ALMDT MediantechnPairCorr
  0.64BUI Barbara Bui SAPairCorr

Moving against Novacyt Stock

  0.54ALMDP Medesis Pharma SAPairCorr
The ability to find closely correlated positions to Novacyt could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novacyt when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novacyt - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novacyt to buy it.
The correlation of Novacyt is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novacyt moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novacyt moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novacyt can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Novacyt. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Novacyt Stock analysis

When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Please note, there is a significant difference between Novacyt's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novacyt is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novacyt's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.